The inhibition of early stages of HER-2/neu-mediated mammary carcinogenesis by dietary n-3 PUFAs

Molecular Nutrition and Food Research

Volumn 57, Issue 2, 2013, Pages 320-327

  Yee, Lisa D ^a,b   Agarwal, Deepak ^b   Rosol, Thomas J ^a,b   Lehman, Amy ^b   Tian, Min ^a   Hatton, Jennifer ^a   Heestand, Jessica ^a   Belury, Martha A ^a,b   Clinton, Steven K ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; HER 2 neu; n 3 PUFAs

Indexed keywords

CORN OIL; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, MOUSE; FATTY ACID SYNTHASE; FISH OIL; ICOSAPENTAENOIC ACID; PTGS2 PROTEIN, MOUSE;

ANIMAL; ARTICLE; CELL PROLIFERATION; DIET THERAPY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; TRANSGENIC MOUSE;

ANIMALS; CELL PROLIFERATION; CORN OIL; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; FATTY ACID SYNTHETASE COMPLEX; FEMALE; FISH OILS; GENE EXPRESSION REGULATION; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; RECEPTOR, ERBB-2;

MOUSE MAMMARY TUMOR VIRUS; MUS; MUS MUSCULUS; ZEA MAYS;

EID: 84872807972     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201200445     Document Type: Article

References (37)

1. Hynes, N. E., Stern, D. F., The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1994, 1198, 165-184.
2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J. et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
3. Ross, J. S., Fletcher, J. A., The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16, 413-428.
4. van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P. et al., Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. New Engl. J. Med. 1988, 319, 1239-1245.
5. Tsuda, H., Hirohashi, S., Multiple developmental pathways of highly aggressive breast cancers disclosed by comparison of histological grades and c-erbB-2 expression patterns in both the non-invasive and invasive portions. Pathol. Int. 1998, 48, 518-525.
6. Stark, A., Hulka, B. S., Joens, S., Novotny, D. et al., HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J. Clin. Oncol. 2000, 18, 267-274.
7. Guy, C. T., Webster, M. A., Schaller, M., Parsons T. J. et al., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992, 89, 10578-10582.
8. Di Carlo, E., Diodoro, M. G., Boggio, K., Modesti, A. et al., Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab. Invest. 1999, 79, 1261-1269.
9. Yee, L. D., Young, D. C., Rosol, T. J., VanBuskirk, A. M. et al., Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neu-induced breast cancer in mice independently of the PPARg ligand rosiglitazone. J. Nutr. 2005, 135, 983-988.
10. Cardiff, R. D., Anver, M. R., Gusterson, B. A., Hennighausen, L. et al., The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000, 19, 968-988.
11. Reeves, P. G., Nielsen, F. H., Fahey, G. C. J., AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J. Nutr. 1993, 123, 1939-1951.
12. Yee, L. D., Lester, J. L., Cole, R. M., Richardson, J. R. et al., Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. Am. J. Clin. Nutr. 2010, 91, 1185-1194.
13. Yee, L. D., Williams, N., Wen, P., Young, D. C. et al., Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin. Cancer Res. 2007, 13, 246-252.
14. Berruti, A., Generali, D., Bertaglia, V., Brizzi, M. P. et al., Intermediate endpoints of primary systemic therapy in breast cancer patients. J. Natl. Cancer Inst. Monogr. 2011, 2011, 142-146.
15. Fasching, P. A., Heusinger, K., Haeberle, L., Niklos, M. et al., Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011, 11, 486.
16. Khan, Q. J., Kimler, B. F., Clark, J., Metheny, T. et al., Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration. Cancer Epidemiol. Biomark. Prevent. 2005, 14, 786-789.
17. Menendez, J. A., Vellon, L., Mehmi, I., Oza B. P. et al., Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene expression in cancer cells. Proc. Natl. Acad. Sci. USA 2004, 101, 10715-10720.
18. Subbaramaiah, K., Norton, L., Gerald, W., Dannenberg, A. J., Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J. Biol. Chem. 2002, 277, 18649-18657.
19. Reseland, J. E., Haugen, F., Hollung, K., Solvoll, K. et al., Reduction of leptin gene expression by dietary polyunsaturated fatty acids. J. Lipid Res. 2001, 42, 743-750.
20. Yang, Z., Bagheri-Yarmand, R., Balasenthil, S., Hortobagyi, G. et al., HER2 regulation of peroxisome proliferator-activated receptor g (PPARg) expression and sensitivity of breast cancer cells to PPARg ligand therapy. Clin. Cancer Res. 2003, 9, 3198-3203.
21. Flachs, P., Mohamed-Ali, V., Horakova, O., Rossmeisl, M. et al., Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006, 49, 394-397.
22. Degnim, A. C., Visscher, D. W., Berman, HK., Frost, M. H. et al., Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J. Clin. Onocol. 2007, 25, 2671-2677.
23. Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G. et al., Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999, 18, 305-314.
24. Benoit, V., Relic, B., Leval, X. X., Chariot, A. et al., Regulation of HER-2 oncogene expression by cyclo-oxygenase-2 and prostaglandin E2. Oncogene 2004, 23, 1631-1635.
25. Ristimaki, A., Sivula, A., Lundin, J., Lundin, M. et al., Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62, 632-635.
26. Visscher, D. W., Pankratz, V. S., Santisteban, M., Reynolds, C. et al., Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J. Natl. Cancer Institute 2008, 100, 421-427.
27. Howe, L. R., Subbaramaiah, K., Patel, J., Masferrer, J. L. et al., Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002, 62, 5405-5407.
28. Lanza-Jacoby, S., Miller, S. G., Flynn, J., Gallatig, K. et al., The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol. Biomark. Prevent. 2003, 12, 1486-1491.
29. Aronson, W. J., Glaspy, J. A., Reddy, S. T., Henning, S. et al., Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology 2001, 58, 283-288.
30. Clinton, S., Diet, anthropometry and breast cancer: integration of experimental and epidemiologic approaches. J. Nutri. 1997, 127, 916S-920S.
31. Pape-Ansorge, K. A., Grande, J. P., Christensen, T. A., Maihle, N. J. et al., Effect of moderate caloric restriction and/or weight cycling on mammary tumor incidence and latency in MMTV-neu female mice. Nutri. Cancer 2002, 44, 161-168.
32. National Toxicology Program, NTP toxicology and carcinogenesis studies of t-butylhydroquinone (CAS No. 1948-33-0) in F344/N rats and B6C3F(1) mice (feed studies). Natl. Toxicol. Program Tech. Rep. 1997, 459, 1-326.
33. Gharavi, N., Haggarty, S., El-Kadi, A. O., Chemoprotective and carcinogenic effects of tert-butylhydroquinone and its metabolites. Curr. Drug Metab. 2007, 8, 1-7.
34. Gonzalez, M. J., Schemmel, R. A., Gray, J. I., Dugan, L. et al., Effect of dietary fat on growth of MCF-7 and MDA-MB-231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis 1991, 12, 1231-1235.
35. Fung, T. T., Hu, F. B., Holmes, M. D., Rosner, B. A. et al., Dietary patterns and the risk of postmenopausal breast cancer. Int. J. Cancer 2005, 116, 116-121.
36. Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W. et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl. Cancer Inst. 2006, 98, 1767-1776.
37. Sant, M., Allemani, C., Sieri, S., Krogh, V. et al., Salad vegetables dietary pattern protects against HER-2-positive breast cancer: a prospective Italian study. Int. J. Cancer 2007, 121, 911-914.